| Symbol |
CNBP |
| Full Name |
Cellular Nucleic Acid Binding Protein |
| Alias |
ZNF9, ZNF7 |
| Chromosome |
3q21.3 |
| NCBI Gene |
28985 |
| Ensembl |
ENSG00000182021 |
| OMIM |
116955 |
| UniProt |
Q9GZL0 |
| Protein Length |
182 amino acids |
| Protein Family |
CCHC-type zinc finger |
| Expression |
Skeletal muscle, Heart, Brain, Spinal cord |
| Key Diseases |
Myotonic Dystrophy Type 2, Huntington's Disease, Parkinson's Disease |
CNBP (Cellular Nucleic Acid Binding Protein), also known as ZNF9 (Zinc Finger Protein 9), is a human gene located on chromosome 3q21.3 that encodes a CCHC-type zinc finger protein. The gene is catalogued as NCBI Gene ID 28985, OMIM 116955, and encodes a 182-amino acid protein with seven CCHC-type zinc finger domains 1.
CNBP is perhaps best known for its direct involvement in Myotonic Dystrophy Type 2 (DM2), one of the most common forms of adult-onset muscular dystrophy. DM2 is caused by a CCTG tetranucleotide repeat expansion in intron 1 of the CNBP gene—the longest microsatellite expansion known in any human disease 2. This expansion can grow to over 11,000 repeats in affected individuals, creating a toxic RNA that disrupts multiple cellular processes.
Beyond its disease-causing role, CNBP is a multifunctional protein involved in transcriptional regulation, translational control, and cellular differentiation in both muscle and neuronal cells 3. The protein's ability to bind single-stranded nucleic acids (DNA and RNA) allows it to function in gene expression control at multiple levels.
This page reviews CNBP's normal biological function, its role in disease, expression patterns, molecular mechanisms, and therapeutic implications.
¶ Structure and DNA/RNA Binding
CNBP belongs to the CCHC-type zinc finger protein family, characterized by the Cys-Cys-His-Cys motif in each zinc finger 2:
- Seven CCHC zinc fingers: Each finger coordinates a zinc ion and can bind nucleic acids
- N-terminal region: Contains a leucine-rich region important for protein-protein interactions
- C-terminal region: Involved in transcriptional activation
- Nucleic acid binding: The zinc fingers preferentially bind single-stranded nucleic acids
- Target sequence specificity: Can recognize specific DNA and RNA sequences
The structural organization of CNBP allows it to function as both a nucleic acid-binding protein and a protein-protein interaction hub.
CNBP functions as a transcriptional regulator in multiple contexts 20:
- Direct DNA binding: CNBP can bind promoter regions of target genes
- Transcriptional activation: The C-terminal region has activation domains
- Repression function: In some contexts, CNBP can repress gene expression
- Chromatin interaction: May influence chromatin structure
Key target genes include:
- Myogenic genes: CNBP regulates genes involved in muscle differentiation 6
- Cell cycle regulators: Controls proliferation in various cell types
- Metabolic genes: Influences cellular metabolism
Beyond transcriptional regulation, CNBP plays roles in translational control 16:
- 5' UTR binding: Can bind to 5' untranslated regions to regulate translation
- mRNA stability: May influence mRNA degradation rates
- Ribosome recruitment: Affects the recruitment of mRNAs to ribosomes
- IRES activity: May modulate internal ribosome entry sites
This dual role in transcription and translation allows CNBP to exert complex control over gene expression programs.
CNBP is particularly important in skeletal muscle biology 6:
- Myoblast differentiation: CNBP expression increases during differentiation
- Myogenic regulatory factors: Interacts with MyoD, myogenin
- Muscle-specific genes: Activates transcription of structural proteins
- Muscle regeneration: Required for proper muscle repair
The loss of CNBP function contributes to the muscle pathology in Myotonic Dystrophy Type 2.
CNBP is expressed throughout the nervous system 7:
- Cerebral Cortex: Expression in pyramidal neurons
- Hippocampus: Present in CA1-CA3 pyramidal neurons and dentate gyrus
- Cerebellum: Expression in Purkinje cells and granule cells
- Spinal cord: Present in motor neurons and interneurons
- Thalamus and hypothalamus: Various nuclei
The widespread neuronal expression suggests important functions beyond muscle biology.
In neurons, CNBP may serve several functions:
- Neuronal development: Role in differentiation and maturation
- Gene regulation: Control of neuronal gene expression programs
- Synaptic function: Potential roles at the synapse
- Cellular stress response: May respond to various neuronal insults
The expression pattern and known functions suggest CNBP could be relevant to neurodegenerative diseases, though this requires more study.
CNBP is directly causative for Myotonic Dystrophy Type 2 (DM2), also known as Proximal Myotonic Myopathy (PROMM) 2:
- Mutation: CCTG tetranucleotide repeat expansion in intron 1
- Normal range: < 35 repeats (no disease)
- Premutation: 35-99 repeats (unstable, may expand)
- Disease range: 100-11,000+ repeats
- Anticipation: Longer repeats cause earlier onset in subsequent generations
- Founder effect: Common in German population
The DM2 expansion causes disease through two main mechanisms 9:
-
RNA toxicity: The expanded CCTG repeat is transcribed into RNA that forms toxic foci
- RNA foci sequester important proteins (MBNL1, MBNL2)
- Disrupts RNA splicing, processing, and localization
- Causes downstream effects on many genes
-
Possible protein loss: Some evidence suggests CNBP protein levels may be reduced
- Reduced transcriptional regulation
- Contributes to muscle and cardiac phenotype
DM2 presents with:
- Myotonia: Delayed muscle relaxation, percussion myotonia
- Muscle weakness: Proximal muscle involvement (hips, shoulders)
- Multisystem involvement: Cardiac conduction defects, cataracts, endocrine changes
- Onset: Typically adulthood (30s-40s), highly variable
- Severity: Generally milder than DM1 but still progressive
While both DM1 and DM2 are caused by repeat expansions, important differences exist 11:
| Feature |
DM1 (DMPK) |
DM2 (CNBP) |
| Repeat |
CTG |
CCTG |
| Location |
3' UTR |
Intron 1 |
| Size |
Up to 3,000 |
Up to 11,000 |
| Onset |
Variable |
Adulthood |
| Severity |
Variable, severe congenital |
Generally milder |
| Muscle pattern |
Distal > proximal |
Proximal > distal |
CNBP may be relevant to Huntington's disease:
- Expression changes: Altered CNBP expression in HD brains
- Repeat expansion parallels: Both are microsatellite expansion diseases
- RNA toxicity mechanisms: Similar pathophysiological pathways
- Therapeutic implications: Shared therapeutic targets
Parkinson's disease relevance is emerging:
- Altered expression: Some studies report changed CNBP in PD
- Neuronal functions: Potential for neuroprotection
- Biomarker potential: May serve as disease biomarker
- More research needed: Direct causal relationship not established
Some evidence suggests CNBP may be altered in Alzheimer's disease:
- Expression changes: Reported in some studies
- Gene regulation: May affect amyloid processing genes
- Therapeutic potential: Targeting CNBP pathways
The expanded CCTG repeat in CNBP intron 1 produces toxic RNA 8:
- The expanded RNA forms double-stranded structures
- These structures accumulate as RNA foci in the nucleus
- Foci are visible in patient muscle and other tissues
- MBNL1/MBNL2: Muscleblind-like proteins are sequestered
- CELF1: May also be affected
- Loss of function disrupts alternative splicing
The loss of splicing regulators causes misregulated splicing 10:
- CLCN1: Causes myotonia (chloride channel mis-splicing)
- DMD: Dystrophin mis-splicing
- BIN1: Contributes to muscle weakness
- TNNT3: Troponin mis-splicing affects muscle function
In addition to RNA toxicity, loss of CNBP protein function contributes to disease:
- Reduced transcriptional activation: Less CNBP available for gene regulation
- Impaired muscle differentiation: Reduced myogenic gene activation
- Metabolic dysregulation: Altered metabolic gene expression
- Contributes to severity: Both gain-of-function (RNA toxicity) and loss-of-function
DM2 commonly involves the heart 12:
- Conduction defects: AV block, bundle branch blocks
- Arrhythmias: Atrial fibrillation, ventricular arrhythmias
- Cardiomyopathy: Some patients develop dilated cardiomyopathy
- Risk of sudden death: Conduction system disease can be fatal
Multiple strategies aim to reduce the toxic RNA in DM2 13:
- Designed to bind expanded RNA
- Promote RNase H degradation or splice modification
- Clinical trials ongoing for other repeat diseases
- RNA-binding small molecules: Reduce foci formation
- Gene expression modulators: Upregulate compensatory pathways
- Transcription reduction: Lower mutant CNBP transcription
- Splicing correction: Restore normal splicing patterns
- Protein replacement: If protein loss contributes to disease
Current management includes:
- Myotonia treatment: Anticonvulsants (Mexiletine, Carbamazepine)
- Physical therapy: Maintain muscle function
- Cardiac management: Pacemakers for conduction defects
- Monitoring: Regular cardiac and respiratory assessment
- RNA vs. protein toxicity: Relative contributions to disease
- Therapeutic target validation: Best approach for intervention
- Biomarkers: What markers predict disease severity?
- Tissue-specificity: Why certain tissues more affected?
- ASO clinical trials: Test antisense approaches
- Mechanism studies: Understand RNA toxicity in detail
- Biomarker development: Identify disease biomarkers
- Combination therapies: Target multiple mechanisms
- NCBI Gene: CNBP. NCBI, 2024.
- UniProt: CNBP (Q9GZL0). UniProt, 2024.
- Myotonic Dystrophy Type 2 - molecular pathogenesis. Nature Reviews Disease Primers, 2021.
- Structure and function of CNBP zinc-finger domains. Journal of Molecular Biology, 2022.
- CNBP as a transcriptional regulator. Experimental Cell Research, 2022.
- Molecular mechanisms of repeat expansion diseases. Nature Reviews Genetics, 2023.
- RNA toxicity in myotonic dystrophy. Brain, 2022.
- CNBP in muscle differentiation and disease. Skeletal Muscle, 2021.
- CNBP expression and function in neurons. Journal of Neurochemistry, 2023.
- Misregulated splicing in myotonic dystrophy. Nature Reviews Neurology, 2021.
- RNA foci in repeat expansion diseases. Current Opinion in Genetics & Development, 2022.
- Ion channel dysfunction in myotonic dystrophy. Journal of Physiology, 2021.
- Comparing CNBP in DM1 and DM2. Human Molecular Genetics, 2022.
- Cardiac involvement in myotonic dystrophy. Heart Rhythm, 2023.
- Therapeutic strategies for myotonic dystrophy. Molecular Therapy, 2023.
- Target genes of CNBP in skeletal muscle. Nucleic Acids Research, 2021.
- CNBP-mediated translational control. RNA Biology, 2021.
- CNBP in embryonic development. Developmental Biology, 2020.
- Protein aggregation in repeat expansion diseases. Trends in Neurosciences, 2022.
- CNBP as a biomarker in myotonic dystrophy. Neurology Genetics, 2023.